These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21964283)

  • 1. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
    Li XH; Li C; Xiao ZQ
    J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?
    Hodgkinson VC; ELFadl D; Agarwal V; Garimella V; Russell C; Long ED; Fox JN; McManus PL; Mahapatra TK; Kneeshaw PJ; Drew PJ; Lind MJ; Cawkwell L
    J Proteomics; 2012 Feb; 75(4):1276-83. PubMed ID: 22115752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards defining biomarkers indicating resistances to targeted therapies.
    Stehle F; Schulz K; Seliger B
    Biochim Biophys Acta; 2014 May; 1844(5):909-16. PubMed ID: 24269379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncoproteomics.
    Joshi S; Tiwari AK; Mondal B; Sharma A
    Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma.
    Chanukuppa V; Taware R; Chatterjee T; Sharma S; More TH; Taunk K; Kumar S; Santra MK; Rapole S
    Curr Top Med Chem; 2018; 18(30):2584-2598. PubMed ID: 30499398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance mechanisms in cancer cells: a proteomics perspective.
    Verrills NM; Kavallaris M
    Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
    Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H
    Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
    Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
    Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer cells acquire resistance to anticancer drugs: an update.
    Lu HP; Chao CC
    Biomed J; 2012; 35(6):464-72. PubMed ID: 23442359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.
    Hodgkinson VC; Eagle GL; Drew PJ; Lind MJ; Cawkwell L
    Cancer Lett; 2010 Aug; 294(1):13-24. PubMed ID: 20176436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances of proteomics technologies for multidrug-resistant mechanisms.
    Zhang T; Yuan Q; Gu Z; Xue C
    Future Med Chem; 2019 Oct; 11(19):2573-2593. PubMed ID: 31633396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into cancer drug resistance from a proteomics perspective.
    An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoresistance mechanisms of breast cancer and their countermeasures.
    Ji X; Lu Y; Tian H; Meng X; Wei M; Cho WC
    Biomed Pharmacother; 2019 Jun; 114():108800. PubMed ID: 30921705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.